Close

FibroGen (FGEN) Receives Fast Track Designation from the U.S. FDA for Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/25/2024

1. META
2. CMG
3. LRCX
4. IBM
5. SPY
6. HCP
7. BSX
8. NOW
9. PI
10. ORCL


Go back to FibroGen (FGEN) Receives Fast Track Designation from the U.S. FDA for Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy
(NASDAQ: FGEN) Delayed: 1.00 +0.02 (2.04%)
Previous Close $0.98    52 Week High $31.90 
Open $0.95    52 Week Low $14.38 
Day High $1.01    P/E N/A 
Day Low $0.90    EPS $0.00 
Volume 566,402